Arbutus Biopharma Unveils Promising HBV Treatment Data

Arbutus Biopharma ( (ABUS) ) has issued an announcement.

On May 7, 2025, Arbutus Biopharma presented data at the EASL Congress 2025, showcasing the potential of imdusiran, an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, in treating chronic hepatitis B (cHBV). The late-breaker poster highlighted that imdusiran, when combined with VTP-300 and low dose nivolumab, achieved a functional cure in some cHBV patients. The Phase 1a/1b trial of AB-101 demonstrated safety and high receptor occupancy without liver dysfunction. These findings suggest promising advancements in HBV treatment, potentially impacting Arbutus’s market position and offering hope for stakeholders in addressing the significant unmet medical need of cHBV.

Spark’s Take on ABUS Stock

According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.

Arbutus Biopharma is currently facing substantial financial and operational challenges. The declining financial performance, coupled with technical indicators pointing to potential volatility and a negative valuation outlook, weigh heavily on the stock’s prospects. Additionally, recent executive changes and legal issues further contribute to the risk profile, resulting in a below-average stock score.

To see Spark’s full report on ABUS stock, click here.

More about Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically developing treatments for chronic hepatitis B virus (HBV) infection. The company is working on RNAi therapeutic imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101).

Average Trading Volume: 1,041,980

Technical Sentiment Signal: Buy

Current Market Cap: $635.7M

Learn more about ABUS stock on TipRanks’ Stock Analysis page.